Sander Slootweg, MSc

Managing Partner

Sander is Managing Partner and co-founded ABN AMRO Capital Life Sciences in 2000 and Forbion Capital Partners in 2006.

Sander is Managing Partner and in addition to his leading role in the investment team and the portfolio, he is responsible for Fundraising, Investor- and Public Relations. On the portfolio management side, he currently serves on the boards of portfolio companies Replimune, NorthSea (Chair), Xention and Oxyrane.

Sander was responsible for two substantial exits: Dezima was acquired by Amgen in 2015 for up to USD 1.55 billion and Biovex was sold to Amgen in March of 2011 for up to USD 1 billion. In recent years Sander has also served on the boards of Ario Pharma, Pulmagen, Fovea (sold to Sanofi in 2009), uniQure (IPO on Nasdaq in 2014), Argenta (sold to Galapagos in 2010), Alantos Pharmaceuticals, Inc. (sold to Amgen in 2007), Impella (sold to Abiomed in 2005), Pieris (IPO on Nasdaq in 2015) and has acted as the Chairman of the Board of AMT (IPO on Euronext in 2007).

Before co-founding Forbion, he was an Investment Director at ABN AMRO Capital Life Sciences. His other activities at ABN AMRO included buy-out/ growth equities at ABN AMRO Capital, Equity Capital Markets Syndications (HQ Amsterdam) and Financial Institutions Relationship Management Latin America (Regional Office Miami).

Sander holds degrees in Business and Financial Economics from the Free University of Amsterdam and Business Administration from Nijenrode University, The Netherlands.

Sander Slootweg
"Investing in the LS space can be very rewarding as financial success is often coupled to success for patients in new drugs and devices for high needs reaching the markets."